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Abstract 1 
It has been well documented that BST2 restricts the release of enveloped viruses by 2 
cross-linking newly produced virions to the cell membrane. However, it is less clear 3 
whether and how BST2 inhibits the release of enveloped viruses which bud via the 4 
secretory pathway. Here, we demonstrated that BST2 restricts the release of Japanese 5 
encephalitis virus (JEV) whose budding occurs at the ER-Golgi intermediate 6 
compartment, and in turn, JEV infection downregulates BST2 expression. We further 7 
found that the JEV envelope protein E, but not other viral components, significantly 8 
downregulates BST2 with the viral protein M playing an auxiliary role in the process.  9 
Envelope protein E-mediated BST2 downregulation appears to undergo lysosomal 10 
degradation pathway. Additional study revealed that the transmembrane domain and the 11 
coiled-coil domain (CC) of BST2 are the target domains of viral protein E and that the N- 12 
and C-terminal membrane anchors and the CC domain of BST2 are essential for blocking 13 
JEV release. Our results together indicate that the release of enveloped viruses whose 14 
budding take place in an intracellular compartment can be restricted by BST2. 15 
 16 
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 3 
Introduction  1 
Bone marrow stromal cell antigen 2 (BST2) is an unusual type II glycoprotein 2 
composed of a short N-terminal cytoplasmic domain, a transmembrane domain, an 3 
extracellular loop and a C-terminal Glycosylphosphatidylinositol (GPI) anchor (Hinz 4 
et al., 2010; Kupzig et al., 2003; Perez-Caballero et al., 2009). A number of viruses 5 
have been reported to be restricted by BST2, including retroviruses (alpha-, beta-, 6 
delta-, lenti-, and spuma-)(Jouvenet et al., 2009), arenaviruses (Lassa virus and 7 
Machupo virus)(Radoshitzky et al., 2010; Sakuma et al., 2009), herpesviruses 8 
(Kaposi's sarcoma-associated herpesvirus and human simplex virus) (Blondeau et al., 9 
2013; Liu et al., 2015; Mansouri et al., 2009; Zenner et al., 2013), filoviruses (Ebola 10 
virus and Marburg virus)(Jouvenet et al., 2009; Sakuma et al., 2009), rhabdoviruses 11 
(vesicular stomatitis virus)(Weidner et al., 2010), paramyxoviruses (Nipah virus), 12 
orthomyxoviruses (influenza A virus)(Watanabe et al., 2011; Yondola et al., 2011), 13 
and flaviviruses (Dengue virus)(Pan et al., 2012). To date, several viral antagonists 14 
have been shown to counteract the restriction of BST2, including the Vpu (Neil et al., 15 
2008), Env (Gupta et al., 2009) and Nef (Jia et al., 2009; Sakuma et al., 2009) proteins 16 
from primate lentiviruses, the K5 protein from KHSV (Mansouri et al., 2009; Pardieu 17 
et al., 2010), the glycoprotein (GP) from Ebola virus (Sakuma et al., 2009), the virion 18 
host shutoff protein (vhs) and glycoprotein M (gM) from HSV-1 (Blondeau et al., 2013; 19 
Zenner et al., 2013), and multiple viral glycoproteins (gB, gD, gH, gL) from HSV-2 20 
(Liu et al., 2015). The fate of BST2 counteracted by viruses remains inconclusive. For 21 
instance, while some studies reported that Vpu mediates BST2 degradation through 22 
proteasomal pathway (Douglas et al., 2009; Mangeat et al., 2009), others suggested 23 
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 4 
that Vpu induces the retention of BST2 within the endolysosomal system with 1 
concomitant partial lysosomal degradation (Iwabu et al., 2009). KSHV K5 promotes 2 
BST2 lysosomal degradation through the ubiquitination of a single lysine residue in the 3 
cytoplasmic domain of the protein, which targets BST2 for transport to lysosomes via 4 
the ESCRT pathway (Mansouri et al., 2009; Pardieu et al., 2010), whereas HIV-2 Env 5 
exclusively sequesters BST2 within the TGN with no concomitant degradation (Hauser 6 
et al., 2010; Le Tortorec and Neil, 2009). 7 
As a broad-spectrum restriction factor against enveloped viruses, the antiviral activity of 8 
BST2 is primarily thought to act on the cell surface, where most viruses acquire their 9 
envelopes by directly budding from the plasma membrane. Of interest, recent studies 10 
reported that human coronavirus 229E and hepatitis C virus, whose assembly take place 11 
in the ER and release from cells via secretory pathway, are inhibited at intracellular 12 
membranes by BST2 (Pan et al., 2013; Wang et al., 2014). BST2 localizes in the plasma 13 
membrane, TGN, and some early endosomal compartments, such as the recycling 14 
endosome compartment (Kupzig et al., 2003). Nevertheless, it remains to be determined 15 
whether the restriction of BST2 on viruses releasing via secretory pathway is viral 16 
species specific.  17 
Japanese encephalitis virus (JEV) is a member of the Flaviviridae family. The infection 18 
of JEV can cause nervous system disease with irreversible neurological damage in 19 
humans and animals (Vaughn and Hoke, 1992). The genome of JEV has one open 20 
reading frame (ORF) encoding a single polyprotein, which is cleaved into 3 structural 21 
proteins - capsid protein (C), precursor membrane protein (prM) and envelope protein (E), 22 
and 7 non-structural proteins - NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5. The 23 
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 5 
genomic RNA of JEV is organized within multiple copies of the C protein, which forms a 1 
nucleocapsid surrounded by a host-derived lipid bilayer containing two viral surface 2 
proteins, prM/M and E (Heinz and Allison, 2003; Kim et al., 2008). JEV assembly and 3 
release are similar to those of human coronavirus 229E and hepatitis C virus (Pan et al., 4 
2013; Wang et al., 2014). JEV progeny virion uses the intrinsic secretory pathways to 5 
bud from the membranes of the endoplasmic reticulum (ER) and Golgi apparatus (Rice, 6 
1996). Whether BST2 restricts the release of JEV has yet to be determined.  7 
In the current study, we investigated whether BST2 plays a role in the release of JEV 8 
progeny virions and the potential mechanisms by which JEV counteracts BST2. Our data 9 
together indicated that BST2 is capable of restricting the release of JEV progeny virions 10 
and that the JEV protein E functions as an antagonist to counteract the restriction of 11 
BST2 by interacting with the TM and CC domains of BST2, leading to its degradation in 12 
the lysosomal pathway. Our findings together support that BST2 is capable of inhibiting 13 
the release of enveloped viruses at both the plasma membrane and intracellular 14 
membranes.  15 
16 
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Results  1 
BST2 reduces the release of JEV progeny virions 2 
To determine whether BST2 is capable of inhibiting the release of JEV progeny virions, 3 
we conducted the virus release assay using two different cell lines, 293T cells which do 4 
not express detectable level of BST2 and HeLa cells which constitutively express BST2. 5 
Firstly, 293T cells were transfected with BST2 expression plasmid (pBST2) or 6 
pcDNA3.1 and then collected at different time points post transfection. The expression of 7 
BST2 was confirmed by Western blot. As shown in Fig. 1A, BST2 displayed several 8 
isoforms, likely due to heterogeneity of glycosylation during post-translational 9 
modification (Andrew et al., 2009). There was no detectable BST2 at 6 hours post 10 
transfection. 293T cells transfected with pBST2 or pcDNA3.1 were infected with JEV at 11 
an MOI of 10 at 6 hours post transfection. At different time points post infection, plaque 12 
assays were conducted to assess the amounts of infectious cell-free virions (SV) and cell-13 
associated progeny virions (CV) containing both extracellular viruses attached to the cell 14 
and intracellular viruses. As shown in Fig. 1B, there was about 2-fold reduction of 15 
infectious cell-free virions in the presence of BST2. In contrast, the titer of CV in BST2-16 
expressing cells was higher than that from pcDNA3.1 transfected cells (Fig. 1C), 17 
suggesting that exogenous expression of BST2 restricts the release of JEV progeny 18 
virions. The antiviral property of endogenous BST2 was also examined in HeLa cells. 19 
Retroviral vectors expressing BST2 shRNA or control shRNA were used. Western blot 20 
showed that, at 48 hours post transfection, all of the four BST2 shRNAs reduced the 21 
expression of BST2 with different efficiency and the most effective shRNA was the 22 
#4BST2 shRNA (Fig. 2A). Subsequently, the #4BST2 shRNA was used in the following 23 
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 7 
experiments. Flow cytometry and western blot analysis indicated that BST2 shRNA 1 
reduced cell-surface and total expression levels of BST2 at 12 hours post-transfection 2 
(Fig. 2B and C). HeLa cells transfected with BST2 shRNA or control shRNA were 3 
infected with JEV at an MOI of 25 at 6 hours post shRNA transfection. The amounts of 4 
SV and CV were analyzed at different time points post infection. As shown in Fig. 2D, 5 
down-regulation of BST2 led to a 2.5-fold increase of SV production, whereas the CV of 6 
the control cells was more than that in the BST2-depleted HeLa cells (Fig. 2E). The level 7 
of protein E in SV or CV were determined by western blot assay at 24 hours post 8 
infection. As shown in Fig. 2F, there was much more protein E in SV in the absence of 9 
BST2. In contrast, the level of protein E in CV of BST2-expressing cells was higher than 10 
that from BST2 shRNA or pcDNA3.1 transfected cells. These data together demonstrated 11 
that BST2 can function as a restriction factor to inhibit the release of JEV progeny 12 
virions.   13 
JEV infection downregulates the expression of BST2 14 
Different viruses have evolved a variety of countermeasures against BST2, the majority 15 
of which cause the removal of BST2 from the cell surface followed by either 16 
sequestration in intracellular compartments or degradation in the lysosomes or 17 
proteasome. For instance, HIV-1 and Sendai virus can downregulate the expression level 18 
of BST2 on the cell surface (Bampi et al., 2013; Douglas et al., 2009). To investigate 19 
whether JEV has a similar capability, we first examined whether JEV infection can 20 
reduce the endogenous expression of BST2. HeLa cells were infected with JEV at an 21 
MOI of 25. At different time points post infection, cells were collected and analyzed. The 22 
total expression level of BST2 was decreased at 36 hours post infection (Fig. S1A), while 23 
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 8 
the cellular localization of BST2 did not changed (Fig. S1B). As shown in Fig. 3A, the 1 
mean fluorescence intensity (MFI) of cell-surface BST2 in infected cells was lower than 2 
that in the mock-infected cells, indicating that the surface expression level of BST2 was 3 
significantly downregulated following JEV infection. Western blot analysis showed that 4 
the total expression level of BST2 was also decreased in the parallel samples (Fig. 3B). 5 
We subsequently investigated whether JEV infection reduced the exogenous expression 6 
of BST2. After 6 hours post transfection with pBST2, 293T cells were infected with JEV 7 
at an MOI of 10. Consistent with the results shown in Fig. 3A and B, JEV infection 8 
significantly decreased cell surface and total expression of BST2 in 293T cells (Fig. 3C 9 
and D). To examine whether BST2 downregulation was due to the depletion of BST2 10 
mRNA as suggested by others (Zenner et al., 2013), BST2 mRNA was measured by real-11 
time PCR. As shown in Fig. 3E, the BST2 mRNA level in JEV-infected cells had no 12 
significant difference compared with that in uninfected cells. These data suggested that 13 
the expression level of BST2 was reduced by JEV infection.  14 
JEV protein E downregulates the expression of BST2 through the lysosomal pathway 15 
Many viruses counteract the function of BST2 to promote the surface removal of BST2. 16 
For instance, HIV-1 encodes Vpu which interacts with BST2 and leads to its degradation 17 
(Douglas et al., 2009; Mansouri et al., 2009). In an attempt to clarify the mechanism of 18 
BST2 degradation caused by JEV, expressing vectors encoding different JEV structural 19 
and non-structural proteins were transfected into HeLa cells, respectively. At 48 hours 20 
post transfection, the surface expression of BST2 was examined by flow cytometry. We 21 
observed that BST2 was downregulated on the cell surface following transfection of 22 
plasmid expressing envelope protein E (Fig. 4A). We compared the downregulation 23 
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 9 
effects of protein E in both HeLa cells and BST2-transfected 293T cells, while HIV-1 1 
Vpu was used as a positive control. As shown in Fig. 4B and C, both cell surface and 2 
total expression levels of BST2 were markedly decreased in protein E-expressing HeLa 3 
cells at 48 hours post transfection. Similarly, the expression of protein E profoundly 4 
reduced the surface and total expression of BST2 in BST2-transfected 293T cells (Fig. 5 
4D and E). To examine whether envelope protein E mediated-downregulation of BST2 6 
undergoes lysosomal degradation, we used a lysosome enrichment kit (Thermo) to isolate 7 
and enrich intact lysosomes from cells transfected with pCAGGS or plasmids expressing 8 
ME-flag. The prepared cell extracts were ultracentrifuged by density gradient 9 
centrifugation. The corresponding bands were collected and the harvested lysosome 10 
pellets were detected by western blot. As shown in Fig. 4F, the lysosome marker 11 
LAMP1, BST2 and protein E all existed in the separated samples from ME-flag-12 
transfected cells. In contrast, only LAMP1 existed in the samples from pCAGGS 13 
transfected cells. To examine whether protein E mediated-downregulation of BST2 14 
undergoes proteasomal degradation pathway, HeLa cells were transfected with pCAGGS 15 
or prME plasmid followed by cultivation in the presence of the proteasome protease 16 
inhibitor (MG132). At 24 hours post transfection, cells were processed for 17 
immunofluorescence staining for subcellular localization of BST2 and a proteasome 18 
marker 20S proteasome, showing that BST2 colocalized with the 20S proteasome in the 19 
presence or absence of protein E (Fig. S2). These data together indicated that protein E 20 
mediated-downregulation of BST2 undergoes lysosomal degradation.  21 
JEV protein M is involved in BST2 downregulation mediated by protein E 22 
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 10 
It has been reported that the prM plays an important role in the intracellular 1 
localization of JEV protein E and that the cell surface expression of protein E could 2 
hardly be detected in the absence of prM (Du et al., 2015). Although prM alone did not 3 
downregulate BST2, whether it plays a role in facilitating the function of protein E on 4 
BST2 downregulation was unclear. Therefore, co-IP experiments were carried out to 5 
assess the role of prM during the process of BST2 downregulation. 293T cells were 6 
cotransfected with plasmids encoding E-flag (the protein E with a flag tag) or prME-7 
flag (the fusion protein of E and prM with a flag tag) and BST2. Precleared cell lysates 8 
were incubated with an anti-flag antibody, and the resulting complexes were analyzed 9 
by western blotting using the antibody against BST2. As shown in Fig. 5A, BST2 was 10 
specifically and effectively precipitated in the presence of protein E. The co-IP 11 
experiments were also performed by pulling down with the anti-BST2 antibody, 12 
followed by western blot with the anti-flag antibody. The flag antibody was able to 13 
specifically precipitate the immune complex that contained the BST2 and E-flag or 14 
ME-flag (Fig. 5B). To preclude a possible interaction between prM and BST2, 293T 15 
cells were contransfected with prM-HA and BST2. The lysates were 16 
immunoprecipitated with the anti-HA antibody and the anti-BST2 antibody, 17 
respectively, showing that prM did not interact with BST2 (Fig. 5C). To further 18 
confirm the interaction of protein E with BST2 in JEV-infected cells, we used JEV to 19 
infect HeLa cells at an MOI of 25. At 48 hours post infection, cells were collected and 20 
assayed by co-IP. The interaction between BST2 and protein E was observed in JEV-21 
infected cells (Fig. 5D). Immunofluorescence assay was also carried out in parallel. 22 
293T cells were cotransfected with plasmids encoding E-flag (the protein E with a flag 23 
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 11 
tag) or prME-flag (the fusion protein of E and prM with a flag tag) and BST2. At 24 1 
hours post transfection, cells were analyzed for colocalization by confocal microscopy. 2 
As shown in Fig. 5E, the JEV protein E co-localized with BST2 on cell surfaces of 3 
both non-permeabilized and permeabilized cells. In the presence of prM, more protein 4 
E was detected on the cell surface than that in the absence of prM (Fig. 5F). Taken 5 
together, these results confirmed a specific interaction between protein E and BST2 6 
and the auxiliary role of prM in this process. 7 
 8 
The TM and CC domains of BST2 are important targets of JEV protein E  9 
To investigate which domain of BST2 is the target of JEV protein E, the interaction 10 
between different BST2 mutants and protein E was examined by coimmunoprecipitation 11 
assay. A panel of BST2 mutants (delCT, delTM, delCC and delGPI) were constructed as 12 
depicted in Fig. 6A and the expression was confirmed by western blot (Fig. 6B). The 13 
precleared cell lysates from transfected cells were incubated with the anti-BST2 antibody 14 
or an isotype control antibody. The precipitates were subsequently analyzed by western 15 
blot using the anti-flag antibody. As shown in Fig. 6C, the BST2 mutants delCT and 16 
delGPI but not delTM and delCC were specifically and effectively precipitated in the 17 
presence of protein E. Furthermore, co-IP assays were performed by pulling down with 18 
the antibody against flag followed by western blot with the antibody against the BST2, 19 
showing that the delCT and delGPI but not delTM and delCC were specifically 20 
coimmunoprecipitated (Fig. 6D). These results suggested that the TM and CC domains of 21 
BST2 are required for its physical interaction with protein E.  22 
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 12 
To further determine which domain of BST2 was essential for its antiviral activity. 293T 1 
cells were tranfected with pcDNA3.1, plasmid expressing wild type BST2 or its mutants 2 
(delCT, delTM, delCC and delGPI), respectively. At 6 hours post transfection, cells were 3 
infected with JEV at an MOI of 10, and the supernatants were collected at 24 hours post 4 
infection followed by the determination of virus titers. As shown in Fig. 6E, like wild 5 
type BST2, mutant delCT inhibited the release of JEV progeny virions, while mutants 6 
delTM, delGPI and delCC did not show such antiviral activity. These data together 7 
demonstrated that the N- and C-terminal membrane anchors and the coiled-coiled domain 8 
of BST2 are required for its inhibition of JEV release. 9 
10 
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Discussion 1 
It has been reported that human coronavirus 229E and hepatitis C virus whose assembly 2 
take place in the ER and release from cells occurs via secretory pathway are inhibited by 3 
BST2 at intracellular membranes, although the underlying mechanism is less clear (Pan 4 
et al., 2013; Wang et al., 2014). In the current study, we found that BST2 restricts the 5 
release of JEV, which core particles bud through the endoplasmic reticulum membrane 6 
and are transported to the secretory pathway via the trans-Golgi network, suggesting that 7 
virions linked to vesicle membranes via BST2 are retained on cells surfaces following the 8 
exocytotic fusion of virion-containing vesicles with plasma membranes. Our findings 9 
indicate that BST2 is a broad-spectrum restriction factor capable of inhibiting virus 10 
budding at both the plasma membrane and the intracellular membranes. JEV infection 11 
downregulated both cell surface and total expression of BST2, implying that the 12 
reduction of BST2 mediated by JEV infection was likely due to protein degradation. 13 
Although BST2 can restrict the release of enveloped viruses, many viruses have evolved 14 
specific antagonists to counteract such antiviral activity. Examples include HIV-1 Vpu, 15 
HIV-2 Env, simian immunodeficiency virus Nef and Env, Ebola and Sendai virus GP, 16 
and KSHV K5. We found that JEV infection significantly downregulated BST2 17 
expression. After examining the structural and non-structural proteins of JEV, we 18 
identified envelope proteins E as the only viral component that downregulated the cell 19 
surface and total expression levels of BST2. Co-IP assays demonstrated a specific 20 
interaction between the viral protein E and BST2, revealing that protein E functions as a 21 
viral antagonist to counteract the restriction by the host. JEV infection or viral protein E 22 
resulted in BST2 degradation in both HeLa cells which constitutively express BST2 and 23 
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293T cells exogenously expressing BST2, indicating that JEV counteracts BST2 in a  1 
cell type and expression mode independent fashion. There are several proposed 2 
mechanisms for viral proteins to antagonize BST2, including lysosomal degradation, 3 
proteasomal degradation, and/or sequestration/retargeting of BST2 to the trans-Golgi 4 
network. Using proteasomal protease inhibitors, immunofluorescence imaging revealed 5 
that BST2 colocalized with the proteasome marker 20S proteasome in the presence or 6 
absence of protein E. Western blot assay showed that protein E and BST2 existed in the 7 
isolated lysosomes of protein E-transfected cells. These together indicate that protein E 8 
promotes the degradation of BST2 via lysosomal pathway. 9 
JEV consists of a nucleocapsid surrounded by a lipid bilayer containing the envelope 10 
glycoprotein and the membrane protein (M). The M protein is derived from a 11 
glycosylated precursor membrane protein (prM) following a cleavage by a furin-like 12 
protease when immature virions are released via the secretory pathway (Mukhopadhyay 13 
et al., 2005). It has been demonstrated that prM is required for the proper folding, 14 
membrane association and assembly of the flavivirus envelope protein E (Konishi and 15 
Mason, 1993; Mukhopadhyay et al., 2005). We found that higher expression level of 16 
protein E was detected in the presence of prM than that in absence of prM, indicating that 17 
prM likely plays an auxiliary role in protein E-mediated BST2 downregulation, likely by 18 
promoting more protein E to interact with BST2. 19 
The N-terminal transmembrane domain (TM) and the C-terminal GPI anchor domain 20 
(GPI) at either end of the coiled-coil domain (CC) of BST2 were showed to be important 21 
for BST2 mediated restriction of HIV-1 and Xenotropic murine leukemia virus-related 22 
virus (XMRV) release (Hu et al., 2012; Perez-Caballero et al., 2009). In our study, 23 
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following construction of a panel of BST2 mutants, co-IP and virus release assays 1 
indicated that the TM and CC domains of BST2 are also essential for the interaction with 2 
protein E and for inhibiting JEV release. Of note, although the GPI anchor does not 3 
directly interact with protein E, it appears to be essential for the antiviral activity of BST2.  4 
In conclusion, our data demonstrated that BST2 is capable of restricting the release of 5 
JEV and in turn JEV infection downregulates the expression of BST2. JEV envelope 6 
protein E functions as an antagonist to counteract the antiviral activity of BST2 while 7 
prM plays an auxiliary role in this process. The TM and CC domains of BST2 are 8 
important for the interaction between protein E and BST2, while the N- and C-terminal 9 
membrane anchors and the coiled-coiled domain of BST2 are required for its inhibition 10 
of JEV infection.  11 
12 
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Materials and Methods 1 
Cells and virus 2 
HeLa, human embryonic kidney 293T (HEK-293T) and baby hamster kidney cell lines 3 
(BHK-21) were maintained in Dulbecco’s Modified Eagle’s medium (DMEM, HyClone) 4 
supplemented with 10% fetal bovina serum (FBS, GIBCO), 100U/ml 5 
penicillin/streptomycin and 2mM glutamine. All cell lines were grown at 37°C in the 6 
presence of 5% CO2. 7 
The JEV strain SA14-14 was propagated in BHK-21 cells utilizing DMEM medium 8 
containing 2% FBS. Virus titer was determined by a plaque-forming assay on BHK-21 9 
cells as previously described (Anand et al., 2010).  10 
Antibodies, plasmids and shRNAs  11 
Rabbit anti-human BST2 antibody was kindly provided by the National Institutes of 12 
Health (NIH). BST2 expressing plasmid (pBST2) was from Origene. Mouse monoclonal 13 
antibody against FLAG was purchased from Sigma (F1804). Mouse monoclonal antibody 14 
against HA (sc-7392) and mouse monoclonal antibody against β-actin (sc-81178) were 15 
purchased from Santa Cruz Biotechnology. Rabbit polyclonal antibody against LAMP1 16 
(ab24170) and mouse monoclonal antibody against JEV glycoprotein E (ab41671) were 17 
purchased from Abcam. 18 
The BST2 mutants delCT, delTM, delCC and delGPI were generated according to the 19 
methods described previously (Perez-Caballero et al., 2009). The ORFs of envelope 20 
protein E, prM and both envelope protein E and prM were cloned into pCAGGS (Tani et 21 
al., 2010) with a flag or a HA tag at the C terminal, termed E-flag, prM-HA and ME-flag, 22 
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 17 
respectively. BST2 shRNA (TG314427) and control shRNA (TG314427) were purchased 1 
from Origene.  2 
JEV release assay 3 
HeLa monolayers were transfected with BST2 or control shRNA using Lipofectamine 4 
2000 (Invitrogen) according to the manufacturer’s instructions. At 6 hours post 5 
transfection, cells were infected with JEV at an MOI of 25. 293T monolayers were 6 
transfected with plasmid expressing BST2 or control plasmid followed by infection with 7 
JEV at an MOI of 10. Two hours later, the medium was removed and replaced with acid-8 
citrate buffer (pH=3) to inactivate extracellular viruses, followed by three washes with 9 
PBS and the addition of fresh medium. The supernatants were collected at different time 10 
points post infection, centrifuged to remove cellular debris and virus titers were 11 
determined by plaque assay on BHK-21 cells. For cell-associated virus titers, cells were 12 
lysed by 3 freeze-thaw cycles, cleared by centrifugation and titered as described above.  13 
Flow cytometry 14 
For BST2 cell surface staining, cells were resuspended in flow cytometry buffer (1×PBS–15 
3% fetal bovine serum), and incubated with a phycoerythrin (PE)-conjugated antibody 16 
against BST2 (12-3179; eBioscience) or isotype-matched PE conjugated IgG1 17 
(eBioscience) for 1 hour on ice. Cells were washed three times with flow cytometry 18 
buffer and fixed with 1% paraformaldehyde. At least 20,000 events were collected for 19 
each sample using FACS Calibur flow cytometer (BD). The mean fluorescence intensity 20 
(MFI) was determined by software Flowjo. 21 
Western blotting 22 
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Cells were lysed in RIPA buffer (0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 1 
150mM NaCl, 10mM Tris[pH7.5], 1mM EDTA), and the samples were separated by 2 
12% SDS-PAGE, followed by transferring onto PVDF membranes. The membranes were 3 
probed with anti-BST2 (1:2000), anti-flag (1:2000), anti-HA (1:2000), anti-protein E 4 
(1:1000), anti-LAMP1 (1:1000) or anti-β-actin (1:1000) antibody for 1 hour at room 5 
temperature, and subsequently washed three times with 0.1% Tween 20/PBS, followed 6 
by an incubation for 1 hour with HRP conjugated goat anti–rabbit secondary antibody 7 
(1:10,000; BA1054, Boster) or HRP conjugated goat anti–mouse secondary antibody 8 
(1:10,000; BA1050, Boster). Following three washes with 0.1% Tween 20/PBS, the 9 
bands were visualized by exposure to FluorChem HD2 Imaging System (Alpha Innotech) 10 
after the addition of chemiluminescent substrate (SuperSignal® West Dura Extended 11 
Duration Substrate; 34075; Thermo Scientific Pierce).  12 
RT-PCR 13 
HeLa cells were infected with JEV at an MOI of 25 or mock infected. At 48 hours post 14 
infection, cells were collected and the total RNA was extracted using Trizol (Invitrogen). 15 
RNase-free DNase I (Fermentas) was used to eliminate the contamination of genomic 16 
DNA. cDNA was then synthesized using moloney murine leukemia virus transcriptase 17 
(Promega). The newly synthesized cDNA was used as the template for the amplification 18 
of a highly specific nucleotide region of BST2 gene. Primers 5′- 19 
CAAACTCCTGCAACCTGACC-3′ and 5′- CATTCTCAAGCTCCTTGATGC-3′ were 20 
used for BST2 amplification. GAPDH was used as an internal control amplified with 21 
primers 5’-GGGAAGCTCACTGGCATGG-3’ and 5’-TTACTCCTTGGAGGCCATGT-22 
3’ (Moltedo et al., 2011). Relative quantitative PCR was performed using a SYBR Green 23 
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Real-Time PCR Master Mix (Toyobo) Dye and an ABI step one real-time PCR system 1 
(Applied Biosystems) as previously described (Chen et al., 2013). The final reaction 2 
conditions were as follow: 95°C for 1 min, followed by 40 cycles of 95°C for 15 sec, 3 
60°C for 15 sec, and 72°C for 45 sec. The difference in gene expression was calculated 4 
on the basis of 2
-ΔΔCT 
values. 5 
Immunofluorescence 6 
To detect the cellular localization of BST2 and JEV protein E, cells on 35mm glass 7 
bottom culture dishes were washed three times with PBS, followed by fixation with 4% 8 
(w/v) cold paraformaldehyde for 10 min at room temperature. Cells were permeabilized 9 
with PBST (PBS-0.2% (v/v) Triton X-100) for 10 min at room temperature and then 10 
blocked with PBS-2% (w/v) BSA for 1 hour at room temperature. Cells were incubated 11 
for 1 hour at 37°C with the anti-flag antibody at a dilution of 1:200 and anti-BST2 12 
antibody at a dilution of 1:200, followed by an incubation for 1 hour at room temperature 13 
with a Alexa Fluor 647-labeled Goat Anti-Mouse IgG(H+L) (A0473, Beyotime) at a 14 
dilution of 1:200 and a Alexa Fluor 488-labeled Goat Anti-Rabbit IgG(H+L) (A0423, 15 
Beyotime) at a dilution of 1:200 in PBS-2% (w/v) BSA. To assess the localization of JEV 16 
protein E on cell surface, cells on 35mm glass bottom culture dishes were washed three 17 
times with PBS, followed by incubation with PBS-2% (w/v) BSA for 1 hour at room 18 
temperature. Cells were then incubated for 1 hour at 4°C with the anti-flag antibody at a 19 
dilution of 1:200 and the anti-BST2 antibody at a dilution of 1:200, followed by 20 
incubation with the Alexa Fluor 647-labeled Goat Anti-Mouse IgG(H+L)(A0473, 21 
Beyotime) at a dilution of 1:200 and the Alexa Fluor 488-labeled Goat Anti-Rabbit 22 
IgG(H+L)(A0423, Beyotime) at a dilution of 1:200 in PBS-2% (w/v) BSA. Cells were 23 
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washed three times with PBS after each incubation. Nuclei were dyed with DAPI 1 
(AR1177, Boster). Stained cells were analyzed using confocal microscopy (PerkinElmer 2 
UltraViewVoX) using a 60 × oil objective with 1.5-fold optical zoom. 3 
Coimmunoprecipitation 4 
Cells were lysed in RIPA buffer [50 mM Tris·HCl, 150 mM NaCl, 0.1% SDS, 0.5% 5 
sodium deoxycholate, 1% Nonidet P-40, protease inhibitors (Roche), pH 7.4] and 6 
sonicated. Lysates were incubated with the anti-flag or the anti-BST2 antibody for 1 hour 7 
at 4°C. Thereafter, sepharose Protein-G beads (Invitrogen) were added and samples were 8 
incubated for an additional 4 hours at 4 °C with rotation. Samples were washed 4 times 9 
with RIPA buffer and resuspended in 2× SDS/PAGE sample buffer. Proteins were 10 
analyzed by immunoblotting with the anti-flag, anti-BST2 or anti-HA antibody. 11 
Statistical analysis 12 
All experiments were repeated for at least three times, and the data are presented as mean 13 
 SD unless otherwise specified. The difference of mean value was analyzed by a paired 14 
Student’s t-test. All statistical analysis was performed by GraphPad Prism. P < 0.05 was 15 
considered statistically significant. 16 
17 
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Figure Legends 1 
Fig. 1. Overexpression of BST2 decreases the release of JEV progeny virions. (A) 293T cells 2 
were transfected with pBST2 or pcDNA3.1, harvested at different time points, lysed and the total 3 
expression of BST2 was detected by western blot. (B and C) 293T cells were transfected with 4 
pBST2 or pcDNA3.1. At 6 hours post transfection, cells were infected with JEV at an MOI of 10. 5 
The titers of supernatant virus (SV) or cell-associated virus (CV) were determined by plaque 6 
assay at the indicated time points post infection. Data shown are mean ± SD of three independent 7 
experiments with each condition performed in triplicate. Compared to pcDNA3.1, *P<0.05; 8 
**P<0.01; ***P<0.001. 9 
 10 
Fig. 2. Downregulation of endogenous BST2 enhances the release of JEV progeny virions. (A) 11 
HeLa cells were transfected with BST2-specific shRNA or control shRNA. At 48 hours post 12 
infection, cells were harvested and lysed for western blot analysis. (B and C) HeLa cells 13 
transfected with BST2 shRNA or non-targeting shRNA were collected at different time points 14 
and analyzed by western blot (B) and flow cytometry (C). (D and E) HeLa cells were infected 15 
with JEV at an MOI of 25 following 6 hours transfection with BST2-specific shRNA or control 16 
shRNA, and the titers of supernatant virus (SV) or cell-associated virus (CV) were determined 17 
by plaque assay at the indicated time points. (F) HeLa cells were infected with JEV at an MOI of 18 
25 following 6 hours transfection with BST2 shRNA or control shRNA. 293T cells were 19 
transfected with pBST2 or pcDNA3.1. The levels of protein E in SV or CV were determined by 20 
western blot assay at 24 hours post infection. Data shown are mean ± SD of three independent 21 
experiments with each condition performed in triplicate. Compared to control shRNA, *P<0.05; 22 
**P<0.01; ***P<0.001. 23 
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Fig. 3. JEV infection downregulates the expression of BST2. (A) HeLa cells were mock-infected 1 
or infected with JEV at an MOI of 25. At 48 hours post infection, cells were fixed and probed 2 
with PE-conjugated anti-BST2 antibody. Cells were then analyzed by flow cytometry. The bar 3 
graph is mean ± SD of MFI from three independent experiments with one representative 4 
histogram being shown. (B) At 48 or 72 hours post infection, HeLa cells infected or uninfected 5 
with JEV were collected and analyzed by western blot. (C) 293T cells were transfected with 6 
plasmid expressing BST2 or empty plasmid. At 6 hours post transfection, cells were infected 7 
with JEV, collected at 24 hours post infection and stained with anti-BST2 antibody for flow 8 
cytometry analysis. The bar graph is mean ± SD of MFI from three independent experiments 9 
with one representative histogram being shown. (D) At 24 hours or 48 hours post infection, 293T 10 
cells infected or uninfected with JEV were collected and analyzed by western blot. One 11 
representative experiment out of three is shown. (E) HeLa cells were transfected with control 12 
shRNA or BST2 specific shRNA, infected with JEV at an MOI of 25. 293T cells were 13 
transfected with empty plasmid or plasmid expressing BST2, infected with JEV at an MOI of 10. 14 
The total RNA of the samples was extracted, and the BST2 mRNA was determined by RT-PCR. 15 
The mRNA level of GAPDH was scored in parallel and used as an internal control. Data shown 16 
are mean ± SD of three independent experiments. 17 
 18 
Fig. 4. JEV envelope protein E antagonizes BST2. (A) HeLa cells were transfected with plasmid 19 
expressing the structural or non-structural proteins of JEV. The surface expression of BST2 was 20 
analyzed by flow cytometry (left), while the total expression of JEV proteins was analyzed by 21 
western blot (right). (B) HeLa cells were transfected with plasmid expressing HIV-1 Vpu, JEV 22 
envelope protein E and control plasmid pcDNA3.1(+), and the cell surface expression of BST2 23 
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was analyzed by flow cytometry. The bar graph is mean ± SD of MFI from three independent 1 
experiments with one representative histogram being shown. (C) The total expression level of 2 
BST2 in the parallel samples of (B) was analyzed by western blot. (D) The cell surface 3 
expression level of BST2 on 293T cells transfected with plasmid expressing BST2 alone or 4 
cotransfected with plasmids expressing BST2 and JEV protein E or HIV-1 Vpu. The bar graph is 5 
mean ± SD of MFI from three independent experiments with one representative histogram being 6 
shown. (E) The total expression level of BST2 in the parallel samples of (D) was analyzed by 7 
western blot. (F) Examination of protein E-mediated BST2 degradation. HeLa cells were 8 
transfected with pcDNA3.1 or plasmid expressing gE-flag. The prepared cell extracts were 9 
ultracentrifuged by density gradient centrifugation and the lysosome band was located in the top 10 
2 mL of the gradient. The corresponding bands were collected and the finally harvested 11 
lysosome pellets were detected by western blot. One representative experiment out of three is 12 
shown. 13 
 14 
Fig. 5. JEV protein E physically interacts with BST2. 293T cells were cotransfected with pBST2 15 
and plasmid expressing E-flag, ME-flag or M-HA. At 48 hours post transfection, cell lysates 16 
were analyzed by co-IP. Co-IP was pulled down using the anti-BST2, anti-flag or anti-HA 17 
antibody. Proteins were immunoprecipitated with the anti-flag (A) or anti-BST2 antibody (B) as 18 
indicated. (C) Proteins were immunoprecipitated with the anti-HA or anti-BST2 antibody as 19 
indicated. (D) HeLa cells were infected with JEV at a MOI of 25. At 48 hours post infection, cell 20 
lysates were analyzed by co-IP. Co-IP was pulled down using the anti-BST2 antibody. One 21 
representative experiment out of three is shown. (E) Colocalization of BST2 with JEV E-flag or 22 
ME-flag. 293T cells cotransfected with pBST2 and plasmid expressing E-flag or ME-flag were 23 
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costained with anti-flag (red) and anti-BST2 (green) antibodies. Nuclei were counterstained with 1 
DAPI (blue). Representative confocal images from three independent experiments are shown. 2 
Scale bars in all panels represent 10μm. (F) HeLa cells were transfected with plasmid expressing 3 
protein E. The surface expression of BST2 was analyzed by flow cytometry.  4 
 5 
Fig. 6. Mapping of BST2 domains essential for its anti-JEV activity. (A) Schematic 6 
representation of the BST2 mutants. (B) 293T cells were cotransfected with pE-flag and plasmid 7 
expressing wild type BST2 or BST2 mutants. At 48 hours post transfection, cells were collected 8 
and lysed. The expression of BST2 mutants in 293T cells was confirmed by Western blot. (C) 9 
and (D) The interaction between protein E and BST2 mutants in the parallel samples of (B) was 10 
analyzed by Co-IP. (E) 293T cells were transfected with pcDNA3.1 or wild type BST2 or BST2 11 
mutants. At 6 hours post transfection, cells were infected with JEV at an MOI of 10 and the 12 
relative viral production of JEV was assessed by viral release assay. One representative 13 
experiment out of three is shown. 14 
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